COMPASS THERAPEUTICS, INC. Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Adjustment
COMPASS THERAPEUTICS, INC. (CMPX) reported Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Adjustment of $651.00 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsAdjustment · last filed 2021-11-12
- COMPASS THERAPEUTICS, INC. deferred finance costs, own-share lending arrangement, issuance costs, adjustment for the quarter ending 2020-09-30 was $651.00K.
| Period end | Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Adjustment 3 month |
|---|---|
| 2020-09-30 | $651.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |